Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results And New Data Reinforcing Strategic Focus In Kidney Disease
Stay updated with breaking news from Danne Doering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
24.04.2024 - Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date ...
Investegate announcements from Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
Vivoryon Therapeutics N.V. Extraordinary General MeetingApproved Appointment of New Executive Directors to the Board Halle / Munich, Germany, September 15, 2023 – Vivoryon Therapeutics N.V. , a...
Vivoryon Therapeutics N.V. Extraordinary General MeetingApproved Appointment of New Executive Directors to the Board Halle (Saale) / Munich, Germany,...